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Five unrelated subjects with dysfunctional coagulation factor VII (FVII) were studied In order to Identify missense
mutations affecting function. Exons 2 to 8 and the Intron-oxon Junctions of their FVII genes were amplified from
peripheral white blood cell DNA by PCR and screened by SSCP analysis. DNA fragments showing aberrant mobility
were sequenced. The following mutations were Identified: In case 1 (FVIhC < 1 % , FVIhAg 18%) a heterozygous
A to G transition at nucteotlde 8915 In exon 6 results In the amlno add substitution Lys-137 to Glu near the C-
termlnus of the FVIIa light chain; In case 2 (FV1I:C 7%, FVIIrAg 47%) a heterozygous A to G transition at nucleotide
7834 In exon 5 results In the substitution of Gln-100 by Arg In the second EGF-IIke domain; In case 3 (FVII:C
20%, FVILAg 76%) a homozygous G to A transition at nudeotlde position 6055 In exon 4 was detected resulting
In substitution of Arg-79 by Gin In the first EGF-IIke domain; In case 5 (FVII:C 10%, FVIhAg 52%) a heterozygous
C to T transition at nucleotide position 6054 In exon 4 also results in the substitution of Arg79, but In this case
It Is replaced by Trp; case 4 (FVIhC < 1 % , FVIhAg 100%) was homozygous for a previously reported mutation
(G to A) at nucleotide position 10715 In exon 8, substituting Gin for Arg at position 304 in the protease domain.
Cases 1, 2 and 5 evidently have additional undetected mutations.
INTRODUCTION
Factor VII (FVII) is a trace vitamin K-dependenl plasma
glycoprotein that circulates in blood as a single-chain zymogen
composed of 406 amino acid residues (Mr 50,000) (1). Upon
vascular injury and in the presence of calcium, FVH forms a
one-to-one stiochiometric complex with its cell surface co-factor
tissue factor (TF). Once complexed to TF, FVH is cleaved to
its active form, factor Vila (FVIIa) and rapidly converts zymogen
factor X and factor EX to the active enzymes. The formation of
an active complex between TF and FVKa is widely thought to
represent the primary stimulus for blood coagulation.
FVII zymogen is converted to its active form by proteolytic
cleavage at a single site (Arg 152-De 153), resulting in a two
chain molecule composed of an N-tenninal light chain, linked
by a single disulphide bridge to a C-terminal heavy chain. The
light chain largely consists of an amino terminal y-
carboxyglutamic acid rich domain, followed by two epidermal
growth factor (EGF)-like domains. The heavy chain consists of
the serine protease catalytic domain. The FVK gene consists of
nine exons; exons la and lb encode the 5' untranslated region
and most of the pre-pro leader sequence whereas exons 2 - 8
encode the mature protein (2).
Hereditary FVK deficiency is a rare coagulopathy, with an
estimated incidence of 1 in 500,000 and only about 150 cases
have been reported. The clinical expression of FVK deficiency
is variable, and despite its key role in coagulation initiation there
often appears to be little correlation between residual FVEt activity
measured in vitro and haemorrhagic symptoms in cases of
congenital deficiency: the reasons for this discrepancy are not
understood (3,4). In the present study, we have sought missense
mutations in the FVK genes of five unrelated subjects with
dysfunctional factor VK variants not associated with bleeding
symptoms, by PCR-SSCP analysis and DNA sequencing.
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RESULTS
Exons 2 to 8 and the intron-exon junctions of the FVII genes
of five unrelated patients with dysfunctional FVII variants were
amplified by PCR. The PCR products with the exception of exon
7 snowed one distinct band of appropriate size on agarose gel
electrophoresis, and no differences were detected between the
subjects and normal controls. The PCR products from exon 7
showed one major DNA band and either one or two minor bands
when analyzed by agarose gel electrophoresis. A polymorphic
repeat at the 3' exon-intron junction of exon 7 has previously
been described and may account for the minor bands observed
(5,6). SSCP analysis of PCR products from exon 7, however,
revealed no difference in mobilities between FVII variant samples
and normal subjects analysed in parallel.
SSCP analysis identified only a single PCR product with
aberrant mobility relative to the normal control in each of the
FVII variants. In case 1, two extra bands with slower migration
were observed for exon 6 (Fig. 1 A). In case 2, a band with slower
migration than the corresponding normal control was seen for
exon 5 (Fig. IB). Exons 3 and 4 were amplified and analyzed
as a single product, and in cases 3 and 5 these products showed
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Figure 1. PCR-SSCP analysis in the FVII gene in five unrelated dysfunctional
F VII variants. A: cue 1, B: cue 2, C: case 3, D: case 4 and E: case 5 snow
the results of PCR-SSCP analysis of exon 6, exon 5, exons 3 and 4, exon 8 and
exons 3 and 4 mrfmting intron/exon junctions respectively. PCR-SSCP analysis
of exons 3 and 4 followed digestion wkfa Dde I digestion, and exon 8 after Nar
I digestion. Arrows indicate extra bands wfch altered migration, when compared
with normal control bonds. 1 and 2: normal controls, 3: FVH variant
aberrant mobility. To further localize the mutation, the PCR
products were digested with the restriction endonuclease Dde I
which cuts within intron 3. Subsequent SSCP analysis showed
the shifted fragment to be associated with exon 4 in both cases
(Fig. 1C, E). Exon 8 was amplified as a single product, but being
too large for SSCP analysis was digested with various restriction
endonucleases prior to analysis. The primary PCR product was
640bp and the fragment sizes following digestion with the
restriction endonucleases were: Nar I, 289 and 351bp; BstX I,
299 and 341bp; and Pst I, 275 and 365bp. In case 4, two extra
bands with slower migration than the normal control were
observed following digestion with Nar I (Fig. ID). However,
no difference in migration was observed following digestion with
either BstX I or Pst I (data not shown).
To determine the nucleotide substitution responsible for the
altered electrophoretic mobilities detected by SSCP analysis, each
of the PCR-amplified DNA fragments was cloned and sequenced
(Table 1).
Substitution of A by G at position 8915 was detected in exon
6 of case 1. As a result, the AAA codon for Lys-137 is replaced
with the codon GAA for Glu. 9 of the 10 clones sequenced
contained the mutant FVQ sequence and 1 the wild type FVH
sequence. Based on the SSCP analysis (Fig. 1A) this individual
is most probably heterozygous for the mutation. The sequence
was confirmed on both sense and antisense strands but no
restriction enzyme site is created or destroyed to enable direct
confirmation of heterozygosity.
In case 2, an A to G substitution was identified at nucleotide
position 7834 in exon 5. The sequence of 5 of the 10 clones had
the A to G substitution and the remainder corresponded to the
wild type sequence. To confirm this mutation, the amplified DNA
fragment including exon 5 and adjacent intron junctions was
digested with the restriction endonuclease Sea I. The mutation
abolishes a Sea I restriction site by changing the sequence from
AGTACT to GGTACT. Three bands were observed
corresponding to undigested DNA and the appropriate size
fragments diagnostic for the presence of the Sea I site. It was
concluded from the sequence and restriction analysis that this
patient was heterozygous for the A to G transition at position
7834, which results in the substitution of Gin-100 by Arg.
In case 3, a point mutation of G to A was found in exon 4
at nucleotide position 6055, resulting in the substitution of Arg-79
by Gin. All ten clones sequenced corresponded to the mutant
FVII sequence. The hctnozygosity of this mutation was confirmed
by loss of an Msp I restriction endonuclease site.
In case 4, transition of G to A was detected in exon 8 at
nucleotide position 10715. This results in the substitution of Arg
Table 1. Phenotype and genotype daa from five (actor VH variants
Case No. FVTIC* u.dl"1 FVHAg+ u.dl -1 Exon SSCP analysis* Nucleotide position' Base change AA change Restriction enzyme analysis!
7
20
10
18
47
76
100
52
6
5
4
8
4
Hctcro
7
Homo
Homo
Homo
8915
7834
6035
10715
6054
AAA to GAA
CAGtoCGG
COG toCAG
CGGtoCAG
CGGtoTOG
Lys-137-Ohi
Gln-100-Arg
Arg-79—On
Arg-304-Gln
Arg-79-Trp
N.D.
Hetero (Scu I)
Homo(MpI)
Homo (M*P I, Pv n
Hetero (Mqp I, Hoe
'Determined by one stage rifting assay using FVH tWirUn^ pi««m« m j rabbit bi nboplasti
+Assayed using an ELJSA kit (Diagnostica Stago.France) based on a porydonal antibody to human FVH. A normal pooled plasma, assumed to contain lOOu.dl-1
of FVH:C and FVH:Ag wai used u control in both mays.
INumbered according to O'Hara et al (2).
•Hetero - heterozygous mutant/wild type; Homo - homorygous mutation. N.D. - Not determined. ? - Indeterminate. Restriction nn*nnndf*w* used to confirm
the imriaipni are given in parentheses.
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by Gin at p i t i o n  304 in th catalytic domain of FW. All ten 
clones displayed the mutam FM sequence, strongly suggesting 
that this individual is homoygous for the mumion. This was 
confirmed by mtriction endonuclease d igdon ,  the mumion 
resulting in h e  crtation of a Pvu I1 site and the l a  of an Msp 
I site. 
In case 5, a C to T transition was identified in exon 4 at 
nucltotide 6054, d t i n g  in h e  substitution of Arg-79 by Trp. 
In t i i s  case, the individual was heteroygous for the mutation 
as determined by sequence analysis and by the haerozygau loas 
of a Hue III restriction r lease site. 
DISCUSSION 
Determination of mutations in dysfunctional FW ~l~olecules 
providesimpormtinformahmtoaccompanypro&inmodelling 
and structurofunction audks. In this study, we have undacaLen 
gem& analysis of five unrelated subjects who pcwsess 
d y s f u m o n a l F W v a r i a n t s . I n d c a s e s , ~ w u e d a e a e d  
in exom using PCRSSCP analysis Fable 1). Tbc mmhm werc 
then idcntifitd by sequencing cloned DNA and confirmed by 
resaiction endonucltasc d i g d o n  in 4 out of 5 c . .  Three of 
the mutarions detected have wt previously btcn rcportal (cases 
1, 2 and 9, om (case 3) bas been described ia a compouod 
homozygote (7) and we have previously d e s c n i  the mutation 
in case 4 in an unrelated iodividual (8). TIE three mucations in 
axhm 79 and 304 occur in CpG dinwleatidts, a h w n  hocepot 
for human g c a  mutation, and are either C-T or G-A 
transitions amsistcnt with a model of methylation-mdiated 
deaminaeion of 5-mdhylcytosim (reviewed by Cooper & 
K m w d  (9)) 
The rqllacermrt of Lys-137 by Glu (case 1) in the connecting 
domain of FW is a radical subseitlbion, since the native lysine 
side chain is largc and positively charged at physiologxal pH, 
wbereas the glutamate group is smaller with a negative charge. 
This residue is adjacent to Cys-135 which forms a disulphidc 
bridge with Cys-262 linking the light and h v y  chains of F W .  
It is difkadt to predict the e .  of such an amino acid s a b d u t h  
but the alteration of charge and shape and the resultant 
cadonnational change of this region of the molecule mi@ 
interfere with chain folding and subsequent disulphide bod 
formation. 
The mutation identified in case 2 results in the substitution of 
Arg for Gh100 in the second EGF* domain (EGF2). Girt-100 
is highly conserved within the EGF2 Qomain of the vieamin K 
depenQent scrim protease family. In the f& edition of the 
haemophilia B database (lo), amongst 22 distinct misscmc 
mutations in EGF2 of FIX a missense mutation at the 
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Table 2. PCR condition uied to amplify the bmnan FVII gene
B
nrci
•orla* m i
uu>lt m i
BoBaa FVII
•orina m i
•abblt m i
onicrcLn ra
nxicrcroo nogmricnuD ra
-mere— ra
•aMsa m i
•ovlaa m i
•abbit m i
Figure 3. A. Comparison of the predicted **"inn acid sequences of lnTimn factors
VD (17), DC (18), X (19) and protein C (PrQ (20) beginning at resklue 46: EOF-
UlPB domailM 1 and 2, pirn thr ltnlrfng rryinn m thrr»i+»-ny li*||||iini| nf (far HgM
rlu*BM m shown. B, Comparison of tbc predicted aminoacid sequences of human
(17), bovine (21) and rabbit (22) FVII. Srrpiffirf IUIMMIISUUS were displayed
wing the programs Lineup and Pretty (Genetics Computer Group, 1991). The
•w^ iwiH »^  tjQ numbered according to dv mature hi "nun pvn Kquence. The
coosenauf wpinrg for each comparison is shown.
corresponding position (Gln-97 to Pro) has been described, but
no phenotype data are available.
The mutations identified in cases 3 and 5 result in the
substitution of Arg-79 by Gin or Tip respectively in the first EGF
domain. Chaing and High have reported a FVII variant, FVII
Charlotte, which was a compound homozygote, homozygous for
both Arg-79 to Gin and for Arg-152 to Gin substitutions (7). It
has been reported that the recombinant Arg-79 to Gin mutant
does not bind its cofactor TF (11,12). In contrast, Kazama et
al (13) have recently expressed and characterized recombinant
FVII with the Arg-79 to Gin mutation and report that it exhibits
TF-dependent activity mriiaigiiiriinhlff from plasma derived FVII.
Whilst these conflicting results require further investigation, our
own data support a role for Arg-79 in factor VII structure or
function, since we have iH*ntifii-H two independent mutations at
this residue associated with altered factor VII activity. We have
modelled the EGF1 domain of FVII using the coordinates of the
highly homologous EGF1 domain of FIX previously established
by NMR spectroscopy. The side chain of Arg-79 does not form
part of the integral structure of EGF 1, but is in full solvent contact
on the surface of the domain (Fig. 2A). The replacement of
Arg-79 by Gin results in a change of shape and charge,
Exoo Denaturation AnDealing
2
3and4
5
6
7
8
96°C, 45 i
95.5'C, 30 i
96'C, 30 s
96°C, 60 i
96°C, 45 s
96*C, 45 s
62*C, 15
65°C, 15
58°C, 60
60-C, 60
70°C, 60
72°C, 135
72-C, 120
72'C, 120
72°C, 180
70*C, 128
70*C, 128
The PCR reaction was initially incubated at the denaturation lanamirt for each
exon for 3 nrira before undergoing 30 cycles of PCR using a PCH3 Techne cyder
(Techne, Cambridge).
futhermore, the energy minimised model structure indicates a
change in the orientation of the amino acid side chain (Fig 2B).
Similarily, the substitution of Arg-79 by Trp results in a change
in charge and the presentation of a bulky aromatic side chain
on the surface of the domain (Fig. 2Q. It has been suggested
that the EGF domains of FVII are involved in determining its
binding to its cofactor TF, however, h is not known whether
EGF1, EGF2, or both domains are required to mediate this
interaction (14). A monoclonal antibody whose epitope has been
mapped to residues 51 - 8 8 of FVII has, however, been shown
to inhibit FVH activation and its binding to TF, thus Arg-79 may
be part of a binding she important in mediating the FVH/TF
interaction (12).
The DNA sequences of other members of the family of vitamin
K-dependent serine proteases, factor IX, factor X and protein
C, have been determined. A comparison of the predicted amino
acid sequence of EGF1, EGF 2 and the linker region between
the light and heavy chains (Fig 3A) demonstrates that residues
Arg-79, Gln-100 and Lys-137 are highly conserved. The
equivalent residues in the 4 proteins are either identical or there
is a conservative substitution. Furthermore, a comparison of the
human with the rabbit and bovine FVH sequences demonstrates
complete evolutionary conservation (Fig. 3B).
In conclusion, we have detected missense mutations in five
independent dysfunctional human FVII variants, and we infer
that these amino acid substitutions occur in regions of the
molecule that are functionally important. Consistent with this
view, each mutation results in radical changes of shape and charge
in an amino acid side chain which is highly conserved both within
the family of vitamin K-dependent serine proteases and between
different species. In vitro expression and characterization of the
mutant proteins are in progress in our laboratory in order to
further define the functional effect of these mutations.
MATERIALS AND METHODS
Subjects
Five unrelated individuals from various countries were stndied whose plasmas
rontnin dysfunctional FVH as ^rfiiif^ by reAnrrA FVH activity in dotting tests
using rabbit thmmhi^^min None of these nibjwti has any significant bleeding
tendency sod all were detected *"^ i routine i*** I^MIBI JTI twn& screeosg tor reasoos
nri»T thin m«nifr«t tw in . May FVH activities and antigen levds of these subjects
are shown in Table 1. Genomic DNA was prepared from peripheral blood
leukocytes by «f*»*»iifh*H NXUHI; (15).
DNA ampmVatloii
Exons 2 to 8 of each subject's FVH genes were amplified by PCR using the
otigonudeotides described previously (8). Five hundred nanograms of g^awniir
DNA, 0.5/ig of each oligonodeotide, and 1.5U Taq DNA polymerase (Promega)
were added to 90pl buffer couaiuiug 1.5 mM MgC^, lOmM Tris-HQ (pH 8.3),
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50mM KCL 0.01 * gelatin, 200*M each deoxynudeotide triphosphaie
of cr-^P-dATP (3000 Ci/mmol, 10 mCi/ml). The reaction mixture vm men
SSCP analyst
SSCP analysis w n pa fanned according to the method of Hayasbi tt al (16).
3.5^1 of the PCR product were duuted 10-fbU in 83% fimuuuide, 20mM EDTA,
0.03% bromopbenoi blue md 0.05* xylene cyanol. The samples were then baled
at 80°C for 3 ntm to denature die DNA, imp-cooled on ice for 5 mini, before
loading onto a 4.3% non-denaturing acryUmide gd (%T, 4.5%;%C, 2.23%).
Ekcuopborerii w u pei-fbimed at 40W for 1.3 to 3 noun at 4°C. The gels were
dried before mt""Hi"fl"ill'y AmrJifiwi produca from eion 8 were
with the reatriction endonudeaset Afar I, Pa I and flaX I according to the
manuiactiiFGn hulliMiw »€ prior to SSCP analysB. SmiMyily. PCR prodocts of
exon 3+4 were drgrilrd with the restriction endonucleaac Ddt I digmwu before
SSCP analysis.
DNA dotting and feqnendng
The amplified DNA fragments were gd purified on a 2% agarose gd and doned
tt the EcoR V BIB of the p1"**"'1 vector pBSK (Stratagene, Cambridge, UK).
The intern were stquenced by the dideoxy chain tnmiintinn method using a
T7 DNA sequencing kit (Pharmacia, U.K.). Ten independent clone* were
seojuenced for each fragment.
Moleeatai dung
The first epidermal growth factor like domain of FVII was "vHlfd on die
hOCQOlOflOUS fifTIIU*** ID F I X n»ww* fltVIHH' COOtuIDfltBS DOT t"f- StTUCtOTC QdnVDu
from nuclear magnrrir. resonance spectroscopy (kindly supplied by
Prof. I.D.Campbell, Department of Biochenustiy, Oxford). No insertions or
<ifif^mi were necessary, tnerefore non-conserved residues could be replaced
directly using the Bioporymer mn^itf of Tmigh* n (Biosym Techootogy Inc.,
San Diego, Calif.) on a SJHcoo Graphics Personal Iris. The resulting structure
was subjected to molecular dynamics f^'lw^*1 and energy minimiiwi by die
method of steepest descent. Residue snbstiUMkius were dien made in mil modd
corresponding to die Arg-79-Trp and Arg-79-Gan nmMations described and the
resulting f^ifflirff finally subjected to Authei euei
13. Kunkel, L.M., Smith, K.D. and Boyer, S.H. (1977)
Proc.Natl.AcKLSci.USA, 74, 1243-1249.
16. Hayashi, K. (1991) PCR Meth.Appl., 1, 34-38.
17. Hagen, F.S., Gray, C.L., Ohm, P., Grant, FJ.. Saari, G.C., Woodbury,
R.G., Hart, C.E., msley, M., iOnd, W., KnncM, K. and Davie, EW.
(1986) Proc.Nad.AcacLSd.USA, 83, 2412-2416.
18. YosUtake, S., Schach, B.G., Foster, D.C., Davie, E.W. and KuncM, K.
(1983) Biochemistry, 24, 3736-3730.
19. Leytus, S.P., Poser, D.C., Kunchi, K. and Davie, E.W. (1986)
Biochemistry, 23, 3098-3102.
20. Faster, D.C., Yosnkake, S. and Davie, E.W. (1983) Proceedings Of The
National Academy Of Sciences Of The United States Of America, 82,
4673-4677.
21. Takeya, H., Kawabaa, S., Nakagawa, K., Yamamkni, Y., Miyata, T.,
Iwanagm, S., Takao, T. and giimnniihi^ Y. (1988) J.Biol.Chem., 263,
14868-14877.
22. Brothen, A.B., Clarke, BJ., Sheffield, W.P. and Blajcnman, M A (1993)
Thrombosis Res., 69, 231-238.
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